Core Viewpoint - A class action has been filed against RxSight, Inc. for allegedly misleading investors about product demand and financial performance during a specified period [1][2]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) for cataract surgery in the U.S. [1] - The primary product of the company is the RxSight system, which includes the LAL and the Light Delivery Device (LDD) [1]. Allegations - The complaint alleges that during the class period, RxSight failed to disclose significant issues, including: - Adoption challenges and structural issues leading to declines in sales and utilization [2] - Overstated demand for its products [2] - Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [2]. Financial Performance - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in LDD sales, LAL utilization, and overall revenue [3]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [3]. - Following this news, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025 [3].

Core Viewpoint - A class action has been filed against RxSight, Inc. for allegedly misleading investors about product demand and financial performance during a specified period [1][2]. Group 1: Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) for cataract surgery in the U.S. [1] - The primary product of RxSight is the RxSight system, which includes the LAL and the Light Delivery Device (LDD) [1]. Group 2: Allegations and Financial Performance - The class action alleges that RxSight failed to disclose adoption challenges and structural issues leading to declines in sales and utilization of its products [2]. - The complaint claims that RxSight overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [2]. - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, showing significant declines in LDD sales, LAL utilization, and overall revenue, and lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [3]. - Following this announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025 [3].

Core Viewpoint - A class action has been filed against RxSight, Inc. for allegedly misleading investors about product demand and financial performance during the specified period [1][2]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) for cataract surgery in the U.S. [1]. Allegations - The complaint alleges that RxSight failed to disclose significant adoption challenges and structural issues leading to declines in sales and utilization of its products [2]. - It is claimed that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [2]. Financial Performance - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue [3]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint, with the CEO citing adoption challenges as a primary reason for the sales stall [3]. - Following this announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025 [3].